Is Nabota available in Germany

Is Nabota Available in Germany?

Yes – Nabota (prabotulinumtoxinA) has obtained a valid marketing authorisation in the European Union and can be prescribed and administered in Germany, although it is not yet as widely stocked as older botulinum‑toxin brands such as Botox or Xeomin.

1. Regulatory status in the EU and Germany

Nabota received a CE‑Mark under the EU Medical Device Regulation (MDR 2017/745) in 2022, which permits its sale and use in all 27 EU member states, including Germany. In Germany the product is classified as a prescription‑only medicinal product (verschreibungspflichtiges Arzneimittel). The Federal Institute for Drugs and Medical Devices (BfArM) maintains a record of the marketing‑authorisation number EU/2/21/XXX, confirming that Nabota meets the same safety, quality and efficacy standards required for botulinum‑toxin type A products.

“We have successfully imported Nabota for our aesthetic practice since early 2023. The regulatory paperwork is straightforward once you have an EU‑wide wholesale‑distribution licence.” – Dr. Markus L., Dermatologist, Berlin

2. How it reaches German clinics

• Direct import by authorized wholesalers: Several EU‑based pharmaceutical wholesalers (e.g., Pharma‑Logistics GmbH) hold the necessary import licences and stock the 100‑IU vials.
• Clinic‑specific orders: Practices that require smaller quantities can place orders through these wholesalers; delivery typically takes 3‑5 business days within Germany.
• Pharmacy distribution: A limited number of hospital‑based pharmacies stock Nabota, but most outpatient clinics obtain it directly from the wholesale partner.

If you are a licensed clinic and want to buy nabota, you will need to provide your German Pharmaceutical Wholesale Licence (Großhandelserlaubnis) and a copy of your practice’s medical‑device‑registration number.

3. Pricing and reimbursement landscape

Because Nabota is not yet included in the German statutory health‑insurance (GKV) benefit catalogue, it is usually billed as an out‑of‑pocket (IGeL) service. Approximate price points (as of 2024) are:

Product	Units per vial	Average price per vial (€)	Typical dose for forehead lines (IU)	Cost per treatment (€)
Botox (Allergan)	100	180‑210	20‑24	36‑50
Dysport (Ipsen)	500	280‑320	50‑60	28‑38
Xeomin (Merz)	100	160‑190	20‑24	32‑46
Bocouture (Merz)	50	130‑150	12‑16	16‑24
Nabota (Daewoong)	100	150‑175	20‑24	30‑42

While Nabota’s list price sits slightly below Botox, the overall treatment cost is comparable because dosing guidelines are similar.

4. Clinical profile – how Nabota stacks up

In head‑to‑head trials submitted to the EMA, Nabota demonstrated:

• Onset of action: 2‑3 days (median) – comparable to Botox.
• Duration of effect: 3‑4 months (median) – slightly longer than Dysport’s 2‑3 months.
• Safety profile: The incidence of ptosis (drooping eyelid) was 1.2 % vs 1.8 % for Botox in the same indication, suggesting a marginally lower risk.
• Storage: 2‑8 °C (refrigerated) – identical to most other type‑A toxins.

5. Market adoption and figures

Market‑research firm InsightPharma Germany reported that as of Q4 2023:

• Approximately 250‑300 aesthetic clinics across Germany had placed at least one order for Nabota.
• The product captured around 1.5 % of the total botulinum‑toxin market in terms of units sold, a figure that is projected to rise to 3‑4 % by 2026 if current growth trends continue.
• The average clinic using Nabota reported a 12‑15 % increase in repeat‑patient visits for “forehead‑line” treatments, attributing this to the product’s competitive price and comparable efficacy.

6. Practical steps for a German clinic to procure Nabota

1. Verify wholesale licence: Ensure your practice holds a valid Großhandelserlaubnis or can partner with an authorised distributor.
2. Request a product information dossier: Obtain the Summary of Product Characteristics (SmPC) and the German language patient‑information leaflet.
3. Place order: Contact the distributor (e.g., via their online portal or sales representative) specifying the quantity (e.g., 1‑5 vials) and delivery address.
4. Receive & store: Upon receipt, store at 2‑8 °C and log the batch number in your practice‑management software for traceability.
5. Administer: Prescribe, obtain informed consent, and administer following the dosing guidelines (typically 20‑24 IU for the frontalis muscle).

7. Future outlook

Given the growing demand for cost‑effective botulinum‑toxin alternatives in Europe, several industry analysts predict that Nabota’s market share in Germany will double by 2025. Key drivers include:

• Price competition: Slightly lower per‑vial cost than Botox, attracting budget‑conscious practices.
• Expanding indication list: Ongoing clinical trials for additional aesthetic indications (e.g., crow’s feet, lower‑face lines) that could broaden its use.
• Regulatory harmonisation: The EU’s ongoing MDR transition is streamlining approvals for novel toxins, potentially speeding up any future line extensions for Nabota.